Tyler Shropshire: Caris Life Sciences’ AI Pathology Hypotheses
Tyler Shropshire, Vice President of Global Biopharma Business Development and Head of Real World Data at Caris Life Sciences, shared on LinkedIn about a paper by Yating Cheng et al. published on Communications Medicine:
“In our Communications Medicine publication last Friday, the digital pathology team at Caris Life Sciences hypothesized that,
- Using image features from both H&E and IHC in a dual-modality approach would be superior in the prediction of biomarkers compared to a single-modality model, and
- AI-predicted biomarker status would meet or exceed the prognostic value of the pathologist-annotated status.
What was found? A few things:
- Combining H&E/IHC provided superior predictive performance for most (but not all) biomarkers, particularly where the biomarker is known to exhibit strong morphological correlates – e.g. MSI/MMRd.
- AI-predicted PD-L1 status correlated with patient outcomes more effectively than CPS scores provided by pathologists.
- In many cases, the dual-modality approach outperformed currently available models that rely on a single stream of image features.
Why should we care?
When appropriately validated, tools like these can be leveraged not only as an adjunct to pathologist-led biomarker identification, but also as enhanced stratification tools for Biopharma to leverage in the design of clinical trials. Human-led interpretation of protein expression with their associated scoring thresholds might not be as precise as it otherwise could be with the addition AI.
Congratulations to Matthew Oberley, Ming Chen, George Sledge, Lauren Dickman, Anthony Helmstetter and the rest of the Caris team.”
Title: Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancer
Authors: Yating Cheng, Norsang Lama, Ming Chen, Egbhal Amidi, Mohammadreza Ramzanpour, Md Ashequr Rahman, Joanne Xiu, Anthony Helmstetter, Lauren Dickman, Jennifer R. Ribeiro, Hassan Ghani, Matthew Oberley, David Spetzler and George W. Sledge
Read the full article on Communications Medicine.
More posts featuring Tyler Shropshire.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023